With shares of Facebook (NASDAQ:FB) trading around $23, is FB an OUTPERFORM, WAIT AND SEE or STAY AWAY? Let�� analyze the stock with the relevant sections of our CHEAT SHEET investing framework:
T = Trends for a Stock’s Movement
Facebook is engaged in building products to create utility for users, developers, and advertisers. People use Facebook to stay connected with their friends and family, to discover what is going on in the world around them, and to share and express what matters to them to the people they care about. Developers can use the Facebook Platform to build applications and websites that integrate with Facebook to reach its global network of users and to build personalized and social products. Advertisers can engage with more than 900 million monthly active users on Facebook or subsets of its users based on information they have chosen to share. Social networking has been a powerful movement and tool in recent years that has changed the way many companies and consumers operate. Facebook is a pioneer and a leader in the social network trend that looks to be here to stay. Facebook will see rising profits through its engagement with the increasing user base that social networking is seeing in coming years.
5 Best International Stocks To Buy Right Now: Red Hat Inc.(RHT)
Red Hat, Inc. provides open source software solutions to enterprises worldwide. It also offers enterprise-ready open source operating system platforms. The company provides Red Hat Enterprise Linux, an operating system designed for enterprise computing; JBoss Enterprise Middleware that offers a suite of products for developing, deploying, integrating, and managing distributed, composite, and Web-based applications and services; and Red Hat Enterprise Virtualization for Servers, including Red Hat Enterprise Virtualization Hypervisor, a hypervisor based on KVM technology that converts the Red Hat Enterprise Linux kernel into a virtualization platform; and Red Hat Enterprise Virtualization Manager, a server virtualization management system, which provide capabilities for host and guest operating systems, such as availability, live migration, power manager, storage manager, and system scheduler. It also offers other Red Hat enterprise technologies, which comprise Red Hat MRG t hat integrates open and scalable messaging; Red Hat Developer, which provides integrated development environments and support for application developers; and Red Hat Directory Server that centralizes application settings, user profiles, group data, policies, and access control information into a network-based registry. In addition, the company offers Red Hat systems management solutions, such as RHN, RHN Satellite, Red Hat Customer Portal, and JBoss ON; and infrastructure enterprise technologies, including software development tools, clustering of systems and services, and directory services. Further, it provides consulting, training, and support services. The company sells its enterprise technologies through subscriptions. It has strategic alliances with Advanced Micro Devices, Inc.; and Intel Corporation. The company was formerly known as Red Hat Software, Inc. and changed its name to Red Hat, Inc. in June 1999. Red Hat, Inc. was founded in 1993 and is headquartered in Ral eigh, North Carolina.
Advisors' Opinion:- [By Lee Jackson]
Red Hat Inc. (NYSE: RHT) is another top stock to buy that may exceed third-quarter estimates. The company provides open source software solutions, primarily to enterprise customers worldwide. With 15.4% earnings growth reported in their fiscal first quarter, sales are booming as its Jboss middleware business drives revenue. The consensus price target for this fast growing company is $58.
- [By Rex Crum]
Red Hat (RHT) �plunged more than 12%, to $46.34 a share. Late Monday, the open-source software company reported better-than-expected fiscal second-quarter results, but its billings for new orders of $376 million fell short of analysts��consensus expectations of almost $400 million. Analysts at Pacific Crest Securities and Piper Jaffray also cut their ratings on Red Hat�� stock.
Top Building Product Stocks To Own Right Now: CSB Bancorp Inc (CSBB)
CSB Bancorp, Inc. (CSB), incorporated in 1991, is a financial holding company. The Commercial and Savings Bank of Millersburg, Ohio (the Bank) is a wholly owned subsidiary of the Company. CSB operates primarily through the Bank and its other subsidiaries, providing a range of banking, trust, financial and brokerage services to corporate, institutional and individual customers throughout northeast Ohio. The Bank provides retail and commercial banking services to its customers, including checking and savings accounts, time deposits, individual retirement accounts (IRAs), safe deposit facilities, personal loans, commercial loans, real estate mortgage loans, installment loans, night depository facilities, brokerage and trust services.
Lending Activities
The Bank provides residential real estate, commercial real estate, commercial and consumer loans to customers located primarily in Holmes, Tuscarawas, Wayne, Stark and portions of surrounding counties in Ohio. Commercial loan rates are variable as well as fixed, and include operating lines of credit and term loans made to small businesses, primarily based on their ability to repay the loan from the cash flow of the business. Business assets, such as equipment, accounts receivable and inventory typically secure such loans. Commercial real estate loans are primarily secured by borrower-occupied business real estate. Commercial real estate loans are generally originated with a loan-to-value ratio of 80% or less. Commercial construction loans are secured by commercial real estate and in most cases the Bank also provides the permanent financing. Residential real estate loans carry both fixed and variable rates and are secured by the borrower�� residence. Home equity lines of credit are made to individuals and are secured by second or first mortgages on the borrower�� residence. Installment loans to individuals include loans secured by automobiles and other consumer assets, including second mortgages on personal residences.
Investment Activities
As of December 31, 2011, the Company�� securities available-for-sale totaled $123,026,000. Its portfolio of securities available-for-sale includes the United States treasury securities, the United States Government corporations and agencies, mortgage-backed securities, obligations of states and political subdivisions, equity securities, and corporate bonds.
Sources of Funds
As of December 31, 2011, the Company�� portfolio of deposits included noninterest-bearing demand, interest-bearing demand deposits, savings deposits and time deposits. Short-term borrowings consist of securities sold under agreements to repurchase, short-term advances through Federal Home Loan Bank and federal funds purchased.
Advisors' Opinion:- [By CRWE]
Today, CSBB remains (0.00%) +0.000 at $18.75 thus far (ref. google finance Delayed: 3:53PM EDT July 30, 2013).
CSB Bancorp, Inc. previously reported second quarter 2013 net income of $1.25 million or $.45 per basic and diluted share, as compared to $1.14 million or $.41 per basic and diluted share for the same period in 2012.
Annualized returns on average common equity (��OE�� and average assets (��OA�� for the quarter were 9.32% and 0.88%, respectively, compared with 8.98% and 0.82% for the second quarter of 2012.
Eddie Steiner, President and CEO commented, ��e continue to focus on growing relationships with current and new customers. The bank�� average loan balances have increased 10% in the past year, and although margins remain tight, this growth has provided increases of approximately 4% in net interest income.��/p>
Top Building Product Stocks To Own Right Now: ALCO Stores Inc (ALCS)
Alco Stores, Inc., incorporated on June 2, 1915, is engaged in the business of retailing general merchandise throughout the central portion of the United States of America through a range of department store outlets. The Company�� ALCO stores offer a range of merchandise consisting of approximately 35,000 items, including automotive, commodities, crafts, domestics, electronics, furniture, hardware, health and beauty aids, housewares, jewelry, ladies�� men�� and children�� apparel and shoes, pre-recorded music and video, sporting goods, seasonal items, stationery and toys.
As of February 3, 2013, the Company operated 217 stores in 23 states located in mostly smaller communities in the central United States. The stores average approximately 21,000 square feet of selling space, with an additional 5,000 square feet utilized for merchandise processing, temporary storage and administration.
Advisors' Opinion:- [By Monica Gerson]
ALCO Stores (NASDAQ: ALCS) is projected to post its Q2 earnings.
Digital Cinema Destinations (NASDAQ: DCIN) is estimated to post a Q4 loss at $0.11 per share on revenue of $11.17 million.
Top Building Product Stocks To Own Right Now: OXiGENE Inc.(OXGN)
OXiGENE, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics to treat cancer and eye diseases in the United States. It primarily focuses on the development of vascular disrupting agents (VDAs) that disable and destroy abnormal blood vessels, which provide solid tumors a means of growth and survival, as well as associate with visual impairment in various ophthalmological diseases and conditions. The company?s products include ZYBRESTAT, which is in fosbretabulin in anaplastic cancer of the thyroid (FACT) trial?Phase 2/3 study for the treatment of anaplastic thyroid cancer; in fosbretabulin in advanced lung oncology (FALCON) trial?Phase 2 randomized and controlled study to treat non-small cell lung cancer; in Phase 2 Simon two-stage design study for the treatment of platinum-resistant ovarian cancer; and in Phase 2 randomized controlled study to treat platinum-relapsed but platinum sensitive ovarian cancer. Its products also comprise OXi4503 that is in Phase 1 dose-escalation study for the treatment of acute myelogenous leukemia and myelodysplastic syndromes; Phase 1b dose-ranging study to treat solid tumors with hepatic tumor burden; and Phase 1 dose-escalation study for the treatment of refractory solid tumors. In addition, the company?s products consist of ZYBRESTAT, which is in Phase 2 randomized, double-masked, placebo-controlled, single-dose study for proof-of-mechanism study in polypoidal choroidal vasculopathy. OXiGENE has a strategic collaboration agreement with Symphony Capital Partners, L.P. to support the advancement of ZYBRESTAT for oncology and ophthalmology, and OXi4503. The company was founded in 1988 and is headquartered in South San Francisco, California.
Advisors' Opinion:- [By Bryan Murphy]
In the very short run, OXiGENE Inc. (NASDAQ:OXGN) is overbought and probably due for a setback, not unlike the all the other one-day surges and subsequent pullbacks we've seen from the stock since February of this year. Today's pop from OXGN, however, is quite different than all the rest... this time, it's got a legitimate shot at following through on the upside effort. Ergo, this little biopharma name is actually one of the market's best 'trades' right now.
- [By Bryan Murphy]
For the second time in as many days, I find myself supporting the purchase of a suddenly-bullish stock by saying "this time is different". Yesterday I was talking about OXiGENE Inc. (NASDAQ:OXGN), but today I'm using the term to describe the bullishness that's unfurling with Neurometrix Inc. (NASDAQ:NURO). And just for the record, yes, I know the perils of the "this time is different" argument. I tend to cringe when I hear it, as (too much) experience has taught me that things are rarely different - patterns within the market play themselves out over and over again. In the case of NURO as well as OXGN though, I can put my finger on something specific that we've not yet seen.
- [By Bryan Murphy]
There's no denying that OXiGENE Inc. (NASDAQ:OXGN) has, if nothing else, an interesting pipeline. And for many investors, the prospect of one or two budding winners in development is more than enough reason to jump into a biotech stock. In the case of OXGN, however, there's a far more direct - and no less speculative - reason to become a shareholder. That reason? The stock's going higher.... seriously.
- [By Wallace Witkowski]
Shares of Oxigene Inc. (OXGN) �more than doubled on very heavy volume after the microcap biotech said a mid-stage study of its drug Zybrestat, when used with Roche�� Avastin, showed increased survival in ovarian cancer patients. Oxigene shares rallied 129% to $5.55 , and were one of the most heavily traded issues after hours with more than 4.2 million shares exchanging hands.
Top Building Product Stocks To Own Right Now: Qiagen N.V.(QGEN)
QIAGEN N.V., through its subsidiaries, provides sample and assay technologies worldwide. It offers approximately 500 core consumable products, such as sample and assay kits, and automated instrumentation systems that empower customers to transform raw biological samples into molecular information. The company?s consumable products are used for plasmid deoxyribonucleic acid (DNA) purification, and ribonucleic acid purification and stabilization; genomic and viral nucleic acid purification; nucleic acid transfection; polymerase chain reaction (PCR) amplification; reverse transcription; DNA cleanup after PCR and sequencing; and DNA cloning and protein purification. The company sells the digene HC2 HPV Test, a signal-amplified test for high-risk strains of the human papillomavirus. It also offers co-development services for companion diagnostics, technology licensing and patent sales services, and custom services, including whole genome amplification, DNA sequencing, and non- cGMP DNA production on a contract basis. The company?s instrumentation systems automate the use of sample and assay technologies into solutions for a range of laboratory needs enabling customers to perform nucleic acid sample preparation, assay setup, target detection, and other laboratory tasks. Its automated systems include QIAsymphony, a modular system; Rotor-Gene Q, a rotary real-time PCR cycler system; PyroMark, a high-resolution detection platform based upon the Pyrosequencing technology; QIAcube, a sample processing instrument; QIAxcel for nucleic acid separation in low- to high-throughput laboratories; and ESE-Quant Tube Scanners, an optical measurement device. The company serves customer classes, including molecular diagnostics laboratories; applied testing customers in fields, such as forensics, veterinary diagnostics, and food safety; pharmaceutical research and development groups, and academic researchers. QIAGEN N.V. was founded in 1986 and is headquartered in Venlo, the Netherlands.
Advisors' Opinion:- [By Maria Armental var popups = dojo.query(".socialByline .popC"); popups.forEach]
Qiagen N.V (QGEN).’s test to quantify viral loads on organ transplant patients has been approved by the U.S. Food and Drug Administration under a full premarket approval. The Artus CMV RCQ MDx Kit is the only FDA-approved, polymerase chain reaction-based assay optimized for low- to mid-throughput testing of human cytomegalovirus.
Top Building Product Stocks To Own Right Now: PostNL NV (PNL)
PostNL NV is a Netherlands-based Company active in delivery sector. The Company is engaged in the delivery of documents, small packages and standard parcels. The Company�� business is organized into three segments: Mail in the Netherlands, responsible for mail services in the Netherland, documents management, direct marketing and fulfillment services, and operating over 2,600 shop-in-shop post offices; Parcels, providing parcel services in the Netherlands and Belgium for both domestic and cross-border parcel distribution, and International, operating in the postal markets of the United Kingdom, Germany and Italy, and focusing on domestic addressed mail services. The Company also provides marketing and communication services, fulfillment solutions and e-commerce related solutions. Advisors' Opinion:- [By Inyoung Hwang]
PostNL (PNL) sank 11 percent to 2.48 euros, the biggest decline since Jan. 14. The Amsterdam-based company said sales in the second-quarter were 1.03 billion euros ($1.37 billion), falling short of the 1.04 billion euros predicted by analysts on average. PostNL forecast addressed mail volume in 2013 will drop as much as 11 percent, greater than its previous forecast of no more than 10 percent.
No comments:
Post a Comment